Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

医学 来曲唑 乳腺癌 内科学 临床终点 戈塞雷林 肿瘤科 转移性乳腺癌 随机化 癌症 阿那曲唑 帕博西利布 辅助治疗 三苯氧胺 临床试验 妇科
作者
Dennis J. Slamon,Peter A. Fasching,Sara A. Hurvitz,Stephen Chia,John Crown,Miguel Martı́n,Carlos H. Barrios,Aditya Bardia,Seock‐Ah Im,Denise A. Yardley,Michael Untch,Chiun‐Sheng Huang,Daniil Stroyakovskiy,Binghe Xu,Rebecca Moroose,Sherene Loi,Fran Visco,Valerie Bee-Munteanu,Karen Afenjar,R Fresco,Tetiana Taran,Arunava Chakravartty,Juan Pablo Zarate,Agnes Lteif,Gabriel N. Hortobágyi
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:15 被引量:23
标识
DOI:10.1177/17588359231178125
摘要

Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. New Adjuvant Trial with Ribociclib [LEE011] (NATALEE) is a trial evaluating the efficacy and safety of adjuvant ribociclib plus endocrine therapy (ET) versus ET alone in patients with HR+/HER2− early nonmetastatic breast cancer (EBC). Methods/design: NATALEE is a multicenter, randomized, open-label, Phase III trial in patients with HR+/HER2− EBC. Eligible patients include women, regardless of menopausal status, and men aged ⩾18 years. Select patients with stage IIA, stage IIB, or stage III disease (per the anatomic classification in the AJCC Cancer Staging Manual, 8th edition) with an initial diagnosis ⩽18 months prior to randomization are eligible. Patients receiving standard (neo)adjuvant ET are eligible if treatment was initiated ⩽12 months before randomization. Patients undergo 1:1 randomization to ribociclib 400 mg/day (3 weeks on/1 week off) +ET (letrozole 2.5 mg/day or anastrozole 1 mg/day [investigator’s discretion] plus goserelin [men or premenopausal women]) or ET alone. Ribociclib treatment duration is 36 months; ET treatment duration is ⩾60 months. The primary end point is invasive disease-free survival. Discussion: The 36-month treatment duration of ribociclib in NATALEE is extended compared with that in other adjuvant cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor trials and is intended to maximize efficacy due to longer duration of CDK4/6 inhibition. Compared with the 600-mg/day dose used in advanced breast cancer, the reduced ribociclib dose used in NATALEE may improve tolerability while maintaining efficacy. NATALEE includes the broadest population of patients with HR+/HER2− EBC of any Phase III trial currently evaluating adjuvant CDK4/6 inhibitor treatment. Trial registration: ClinicalTrials.gov identifier: NCT03701334 ( https://clinicaltrials.gov/ct2/show/NCT03701334 )
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
H-China发布了新的文献求助10
刚刚
1秒前
111111完成签到,获得积分10
1秒前
525完成签到,获得积分10
1秒前
THEEVE发布了新的文献求助10
2秒前
lanxinge完成签到,获得积分10
2秒前
LLZ发布了新的文献求助10
2秒前
内向寒云发布了新的文献求助10
3秒前
乐乐应助cmy采纳,获得10
4秒前
NexusExplorer应助捉一只小鱼采纳,获得10
4秒前
123完成签到 ,获得积分10
5秒前
科研小越完成签到,获得积分10
5秒前
要减肥朋友完成签到,获得积分10
5秒前
5秒前
111111发布了新的文献求助10
5秒前
xixi发布了新的文献求助10
6秒前
眼睛大的栾完成签到 ,获得积分20
6秒前
无花果应助wergou采纳,获得10
6秒前
852应助小魏哥哥采纳,获得10
7秒前
鳕鱼完成签到,获得积分10
7秒前
共享精神应助IvyLee采纳,获得10
7秒前
7秒前
Xiaohu完成签到,获得积分10
7秒前
8秒前
今后应助DJDJ采纳,获得10
8秒前
落落完成签到,获得积分10
8秒前
磨人的老妖精完成签到,获得积分10
8秒前
yw完成签到,获得积分10
10秒前
H-China完成签到,获得积分20
10秒前
木木发布了新的文献求助10
10秒前
开心完成签到 ,获得积分10
11秒前
小怪兽完成签到,获得积分10
11秒前
火星上白风完成签到,获得积分10
12秒前
asheng98完成签到 ,获得积分10
12秒前
13秒前
77发布了新的文献求助10
13秒前
clm完成签到 ,获得积分10
14秒前
小野菌完成签到,获得积分10
14秒前
董晴完成签到,获得积分20
14秒前
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3977208
求助须知:如何正确求助?哪些是违规求助? 3521439
关于积分的说明 11207911
捐赠科研通 3258380
什么是DOI,文献DOI怎么找? 1799052
邀请新用户注册赠送积分活动 878108
科研通“疑难数据库(出版商)”最低求助积分说明 806764